查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1797940

全球多组体学市场：未来预测（至 2032 年）—按类型、产品/服务、技术、应用、最终用户和地区进行分析

Multiomics Market Forecasts to 2032 - Global Analysis By Type, Product & Service, Technology, Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，全球多组体学市场预计在 2025 年达到 32 亿美元，到 2032 年将达到 91 亿美元，预测期内的复合年增长率为 15.9%。

多体学是对多个「体学」资料集（包括基因组学、蛋白质组学、转录组学和代谢体学）的整合分析，以全面了解生物系统。透过聚合不同的分子层，多组体学能够实现准确的疾病分析、生物标记发现和标靶治疗的开发。多组体学增强了精准医疗、诊断和药物开发等领域的数据主导决策。

精准医疗和个人化治疗的兴起

多体学透过整合基因组学、转录组学、蛋白质组学和代谢组学数据，创建详细的患者檔案，提供实现此类个人化治疗所需的全面分子洞察。这种综合分析使医疗专业人员能够识别特定的疾病机制，预测治疗反应，并制定有针对性的治疗性介入。此外，癌症、糖尿病和心血管疾病等慢性疾病的日益流行，推动了对个人化治疗解决方案的需求，并促使公共和私营部门在多体学研发方面投入大量资金。

缺乏标准化的分析流程

缺乏标准化的资料整合和解读框架仍然是多体学市场面临的一大挑战，这限制了研究成果的传播和可重复性。各种体学资料集的格式和结构各不相同，使得无缝整合对研究人员来说极为复杂且耗时。此外，开髮用于多组体学分析的稳健计算流程的复杂性，加上专用设备和高技能人员的高昂成本，给小型研究机构带来了巨大的障碍，并限制了市场渗透。

人工智慧/机器学习在多组体学资料分析中的整合

人工智慧演算法擅长整合和分析来自不同体学学科的大量资料集，从而能够更快地识别疾病亚型、药物标靶和生物标记物，加速药物研发进程。云端处理平台正在改变研究人员处理大型复杂多组体学资料集的方式，提供可扩展且经济高效的资料储存和分析解决方案。先进的人工智慧预测模型可以识别特定疾病的风险个体并预测治疗反应，促进更有效的个人化治疗方案的开发，并提高多种医疗应用的诊断准确性。

资料外洩和网路安全事件的风险

欧盟的《一般资料保护规范》（GDPR）和美国的《健康保险流通与责任法案》（HIPAA）等严格的监管要求，对个人基因组和分子资料的收集、储存和共用提出了复杂的合规义务。随着研究网路和云端基础平台的互联程度日益加深，潜在网路威胁的攻击面也随之扩大。涉及多组体学资讯的资料外洩可能会造成深远的后果，包括身分盗窃、歧视以及病患信任的丧失。

COVID-19的影响：

COVID-19疫情显着加速了多体学的研究和应用，彰显了该技术在理解病毒病原体和宿主免疫反应方面的关键作用。调查团队采用整合的多组学体学，对COVID-19患者的血浆蛋白、代谢物和细胞转录物进行了分析，揭示了单体学方法无法捕捉的全面分子图谱。这些研究确定了84种可用于治疗COVID-19的潜在化合物，并透过计算分析发现了6种候选药物。此外，这次疫情凸显了多体学在侦测病毒入侵途径和补体系统活化方面的卓越能力，为治疗性介入策略提供了重要见解。

预计批量多组体学细分市场将成为预测期内最大的细分市场

由于批量多体学学在大规模人口研究、药物研发项目和综合疾病分析应用中的广泛应用，预计在预测期内将占据最大的市场占有率。由于与单细胞方法相比，批量多组学具有成本效益，并且具有成熟的分析工具和通讯协定，因此该方法仍然是多体学工作流程中的标准方法。此外，研究机构和製药公司更倾向于使用批量多组体学进行广泛的基因组研究和生物标记发现项目，因为它能够为不同的患者群体提供可靠的结果。

精准医疗预计将在预测期内达到最高复合年增长率

精准医疗领域预计将在预测期内呈现最高成长率。这得益于多体学数据的独特能力，它能够根据每位患者的分子特征量身定制治疗方案，从而实现更有效、更个性化的医疗结果。该方法结合基因组学、蛋白质组学、代谢体学和其他层面的分子数据，以分析疾病的根本原因并预测患者对不同治疗的反应，从而加深对疾病机制的理解并确定具体的治疗标靶。此外，人们日益认识到，传统的「一刀切」治疗方法不足以应对复杂疾病，这也推动了精准医疗的投资和研究。

占比最大的地区：

在预测期内，北美预计将占据最大的市场占有率，这得益于其强大的科研基础设施、对医疗和生物技术研发的大量投资，以及政府和私营部门资助计划的大力支持。该地区拥有赛默飞世尔科技、Illumina、安捷伦科技和凯杰等领先的生命科学公司，推动多组体学方法和技术的持续创新。美国食品药物管理局 (FDA) 对基于生物标誌物的药物开发的支持性法规环境，加上该地区先进的医疗保健基础设施和对个人化医疗的重视，增强了北美的优势。

复合年增长率最高的地区：

预计亚太地区在预测期内将呈现最高的复合年增长率，这得益于生命科学研究投资的增加、生物技术新兴企业的快速扩张以及医疗保健基础设施的显着改善，尤其是在中国、日本和印度等主要市场。该全部区域的倡议正透过印度国家发展计画和永续目标等综合政策积极推动生物技术的发展，这些政策特别支持生物技术发展和生物製造能力。此外，该地区各种疾病的日益普及推动了人们对新型药物发现应用的更多关注，而中国等国家正透过华大基因集团等公司成为多组体学研究的领导者，大力投资基因组学研究和精准医疗计划。支持性的法规环境、不断增长的医疗保健意识以及政府的战略支持，使亚太地区成为成长最快的区域市场。

产品和服务

  • 装置
  • 耗材
  • 软体和分析平台
  • 服务

免费客製化服务

此报告的订阅者可以从以下免费自订选项中选择一项：

  • 公司简介
    • 对最多三家其他公司进行全面分析
    • 主要企业的SWOT分析（最多3家公司）
  • 区域分类
    • 根据客户兴趣对主要国家进行的市场估计、预测和复合年增长率（註：基于可行性检查）
  • 竞争基准化分析
    • 根据产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第一章执行摘要

第 2 章 简介

  • 概述
  • 相关利益者
  • 分析范围
  • 分析方法
    • 资料探勘
    • 数据分析
    • 数据检验
    • 分析方法
  • 分析材料
    • 主要研究资料
    • 二手研究资讯来源
    • 先决条件

第三章市场走势分析

  • 驱动程式
  • 抑制因素
  • 市场机会
  • 威胁
  • 技术分析
  • 应用分析
  • 最终用户分析
  • 新兴市场
  • COVID-19的感染疾病

第四章 波特五力分析

  • 供应商的议价能力
  • 买方议价能力
  • 替代产品的威胁
  • 新参与企业的威胁
  • 企业之间的竞争

第五章 全球多组体学市场（按类型）

  • 基因组学
  • 转录组学
  • 蛋白质体学
  • 代谢体学
  • 表观基因
  • 脂类组学
  • 微生物组学

6. 全球多组体学市场（按产品和服务）

  • 装置
    • 定序设备
    • 质谱仪
    • 层析法系统
    • 微阵列
  • 耗材
    • 试剂和套件
    • 检测试剂套件
    • 样品製备套件
  • 软体和分析平台
    • 数据整合和视觉化工具
    • AI/ML平台
  • 服务
    • 多组体学资料分析
    • 客製化服务
    • 合约研究服务

7. 全球多组体学市场（按技术）

  • 单细胞多组体学
  • 批量体学
  • 空间体学

第八章 全球多组体学市场（按应用）

  • 药物发现与开发
  • 精准医疗
  • 生物标记发现
  • 临床诊断
  • 农业基因组学
  • 个人化营养
  • 环境调查
  • 微生物组分析
  • 其他用途

9. 全球多组体学市场（依最终用户）

  • 製药和生物技术公司
  • 学术和研究机构
  • 医院和诊所
  • 合约研究组织/合约生产组织
  • 诊断实验室
  • 农业基因组学公司
  • 其他最终用户

第 10 章 全球多组体学市场（按地区）

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 其他欧洲国家
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东和非洲地区

第十一章：主要趋势

  • 合约、商业伙伴关係和合资企业
  • 企业合併与收购（M&A）
  • 新产品发布
  • 业务扩展
  • 其他关键策略

第十二章 公司概况

  • 10x Genomics
  • Agilent Technologies
  • Becton, Dickinson and Company（BD）
  • BGI Genomics
  • Bio-Rad Laboratories
  • Bio-Techne Corporation
  • Bruker
  • Danaher Corporation
  • Illumina
  • Mission Bio
  • NanoString Technologies
  • Oxford Nanopore Technologies
  • Pacific Biosciences（PacBio）
  • Revvity
  • QIAGEN
  • Roche
  • Standard BioTools
  • Shimadzu Corporation
  • Thermo Fisher Scientific
  • Human Longevity, Inc.
Product Code: SMRC30310

According to Stratistics MRC, the Global Multiomics Market is accounted for $3.2 billion in 2025 and is expected to reach $9.1 billion by 2032 growing at a CAGR of 15.9% during the forecast period. Multiomics is the integrated analysis of multiple "omics" data sets genomics, proteomics, transcriptomics, metabolomics, and more to gain a comprehensive understanding of biological systems. By aggregating diverse molecular layers, multiomics enables precise disease profiling, biomarker discovery, and targeted therapeutic development. It enhances data-driven decision-making across sectors such as precision medicine, diagnostics, and drug development.

Market Dynamics:

Driver:

Rise in precision medicine & personalized therapies

Multiomics provides the comprehensive molecular insights necessary to enable this personalized approach by integrating genomic, transcriptomic, proteomic, and metabolomic data to create detailed patient profiles. This integrated analysis allows healthcare professionals to identify specific disease mechanisms, predict treatment responses, and develop targeted therapeutic interventions. Furthermore, the growing prevalence of chronic diseases such as cancer, diabetes, and cardiovascular conditions has intensified the demand for personalized treatment solutions, driving significant investments from both private and public sectors in multiomics research and development.

Restraint:

Lack of standardized analytical pipelines

The absence of standardized frameworks for data integration and interpretation continues to pose significant challenges for the multiomics market, limiting widespread adoption and reproducibility of research findings. Different omics datasets possess varying formats and structures, making seamless integration extremely complex and time-consuming for researchers. Additionally, the complexity of developing robust computational pipelines for multiomics analysis, combined with the high costs associated with specialized equipment and highly skilled personnel, creates substantial barriers for smaller research organizations and limits market penetration.

Opportunity:

Integration of AI/ML in multiomics data analysis

AI algorithms excel at integrating and analyzing vast datasets from various omics fields, enabling faster identification of disease subtypes, drug targets, and biomarkers while accelerating drug discovery processes. Cloud computing platforms are transforming how researchers handle large and complex multiomics datasets, providing scalable and cost-effective solutions for data storage and analysis. Advanced AI-driven predictive models can identify individuals at risk for specific diseases and predict treatment responses, facilitating the development of more effective personalized therapies and improving diagnostic accuracy across multiple healthcare applications.

Threat:

Risk of data breach or cybersecurity incidents

Stringent regulatory requirements such as GDPR in the European Union and HIPAA in the United States impose complex compliance obligations for collecting, storing, and sharing personal genomic and molecular data. The increasing interconnectedness of research networks and cloud-based platforms expands the attack surface for potential cyber threats. Data breaches involving multiomics information could have far-reaching consequences, including identity theft, discrimination, and loss of patient trust.

Covid-19 Impact:

The COVID-19 pandemic significantly accelerated multiomics research and applications, demonstrating the technology's critical role in understanding viral pathogenesis and host immune responses. Researchers utilized integrated multiomics approaches to profile plasma proteins, metabolites, and cellular transcripts from COVID-19 patients, revealing comprehensive molecular landscapes that single omics approaches could not capture. These studies identified 84 potentially active compounds for COVID-19 treatment and led to the discovery of six candidate drugs through computational analysis. Additionally, the pandemic highlighted multiomics' superior ability to detect viral entry pathways and complement system activation, providing crucial insights for therapeutic intervention strategies.

The bulk multiomics segment is expected to be the largest during the forecast period

The bulk multiomics segment is expected to account for the largest market share during the forecast period due to its widespread adoption in large-scale population studies, drug discovery initiatives, and comprehensive disease profiling applications. This approach remains the standard in multiomics workflows because of its cost-effectiveness compared to single-cell alternatives and the availability of well-established analytical tools and protocols. Additionally, research institutions and pharmaceutical companies prefer bulk multiomics for conducting extensive genomic studies and biomarker discovery programs, as it provides reliable results across diverse patient populations.

The precision medicine segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the precision medicine segment is predicted to witness the highest growth rate, driven by multiomics data's unique ability to customize treatments based on individual patient molecular characteristics, resulting in more effective and personalized healthcare outcomes. This approach combines genomics, proteomics, metabolomics, and other molecular data layers to provide deeper understanding of disease mechanisms and identify specific therapeutic targets by analyzing root causes of diseases and predicting patient responses to different treatments. Furthermore, the growing recognition that traditional one-size-fits-all treatment approaches are inadequate for complex diseases continues to drive investment and research.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share owing to its robust research infrastructure, substantial investments in healthcare and biotechnology R&D, and strong support from both government and private sector funding initiatives. The region benefits from the presence of major life science companies, including Thermo Fisher Scientific, Illumina, Agilent Technologies, and QIAGEN, which drive continuous innovation in multiomics approaches and technologies. The FDA's supportive regulatory environment for biomarker-guided drug development, combined with the region's advanced healthcare infrastructure and focus on personalized medicine, reinforces North America's dominant position.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR, fueled by increasing investments in life sciences research, a rapidly expanding number of biotechnology startups, and substantial improvements in healthcare infrastructure, particularly in key markets like China, Japan, and India. Government initiatives across the region actively promote biotechnology growth through comprehensive policies such as India's National Development Programmes and Sustainable Development Goals, which specifically support biotech development and biomanufacturing capabilities. Moreover, the region's growing prevalence of various diseases has intensified focus on novel drug discovery applications, with countries like China emerging as leaders in multiomics research through companies like BGI Group and substantial investments in genomics research and precision medicine initiatives. The combination of supportive regulatory environments, increasing healthcare awareness, and strategic government backing positions Asia Pacific as the fastest-growing regional market

Key players in the market

Some of the key players in Multiomics Market include 10x Genomics, Agilent Technologies, Becton, Dickinson and Company (BD), BGI Genomics, Bio-Rad Laboratories, Bio-Techne Corporation, Bruker, Danaher Corporation, Illumina, Mission Bio, NanoString Technologies, Oxford Nanopore Technologies, Pacific Biosciences (PacBio), Revvity, QIAGEN, Roche, Standard BioTools, Shimadzu Corporation, Thermo Fisher Scientific, and Human Longevity, Inc.

Key Developments:

In June 2025, Illumina, Inc. announced it has entered into a definitive agreement with Standard BioTools under which Illumina will acquire SomaLogic, a leader in data-driven proteomics technology, and other specified assets for $350 million in cash payable at closing, subject to customary adjustments, plus up to $75 million in near-term performance-based milestones and performance-based royalties.

In August 2024, Agilent announced a cooperation agreement with Sangon Biotech to advance nucleic acid research, with particular focus on promoting development in synthetic biology and multi-omics.

In January 2024, BD announced collaboration with Hamilton to develop automated applications and robotics-compatible reagent kits to enable greater standardization in large-scale single-cell multiomics experiments.

Types Covered:

  • Genomics
  • Transcriptomics
  • Proteomics
  • Metabolomics
  • Epigenomics
  • Lipidomics
  • Microbiomics

Product & Services:

  • Instruments
  • Consumables
  • Software & Analytics Platforms
  • Services

Technologies Covered:

  • Single-Cell Multiomics
  • Bulk Multiomics
  • Spatial Multiomics

Applications Covered:

  • Drug Discovery & Development
  • Precision Medicine
  • Biomarker Discovery
  • Clinical Diagnostics
  • Agrigenomics
  • Personalized Nutrition
  • Environmental Research
  • Microbiome Analysis
  • Other Applications

End Users Covered:

  • Pharmaceutical & Biotechnology Companies
  • Academic & Research Institutes
  • Hospitals & Clinics
  • CROs & CDMOs
  • Diagnostic Laboratories
  • Agrigenomics Companies
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Technology Analysis
  • 3.7 Application Analysis
  • 3.8 End User Analysis
  • 3.9 Emerging Markets
  • 3.10 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Multiomics Market, By Type

  • 5.1 Introduction
  • 5.2 Genomics
  • 5.3 Transcriptomics
  • 5.4 Proteomics
  • 5.5 Metabolomics
  • 5.6 Epigenomics
  • 5.7 Lipidomics
  • 5.8 Microbiomics

6 Global Multiomics Market, By Product & Service

  • 6.1 Introduction
  • 6.2 Instruments
    • 6.2.1 Sequencing Instruments
    • 6.2.2 Mass Spectrometers
    • 6.2.3 Chromatography Systems
    • 6.2.4 Microarrays
  • 6.3 Consumables
    • 6.3.1 Reagents & Kits
    • 6.3.2 Assay Kits
    • 6.3.3 Sample Preparation Kits
  • 6.4 Software & Analytics Platforms
    • 6.4.1 Data Integration & Visualization Tools
    • 6.4.2 AI/ML Platforms
  • 6.5 Services
    • 6.5.1 Multiomics Data Analysis
    • 6.5.2 Custom Services
    • 6.5.3 Contract Research Services

7 Global Multiomics Market, By Technology

  • 7.1 Introduction
  • 7.2 Single-Cell Multiomics
  • 7.3 Bulk Multiomics
  • 7.4 Spatial Multiomics

8 Global Multiomics Market, By Application

  • 8.1 Introduction
  • 8.2 Drug Discovery & Development
  • 8.3 Precision Medicine
  • 8.4 Biomarker Discovery
  • 8.5 Clinical Diagnostics
  • 8.6 Agrigenomics
  • 8.7 Personalized Nutrition
  • 8.8 Environmental Research
  • 8.9 Microbiome Analysis
  • 8.10 Other Applications

9 Global Multiomics Market, By End User

  • 9.1 Introduction
  • 9.2 Pharmaceutical & Biotechnology Companies
  • 9.3 Academic & Research Institutes
  • 9.4 Hospitals & Clinics
  • 9.5 CROs & CDMOs
  • 9.6 Diagnostic Laboratories
  • 9.7 Agrigenomics Companies
  • 9.8 Other End Users

10 Global Multiomics Market, By Geography

  • 10.1 Introduction
  • 10.2 North America
    • 10.2.1 US
    • 10.2.2 Canada
    • 10.2.3 Mexico
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 Italy
    • 10.3.4 France
    • 10.3.5 Spain
    • 10.3.6 Rest of Europe
  • 10.4 Asia Pacific
    • 10.4.1 Japan
    • 10.4.2 China
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 New Zealand
    • 10.4.6 South Korea
    • 10.4.7 Rest of Asia Pacific
  • 10.5 South America
    • 10.5.1 Argentina
    • 10.5.2 Brazil
    • 10.5.3 Chile
    • 10.5.4 Rest of South America
  • 10.6 Middle East & Africa
    • 10.6.1 Saudi Arabia
    • 10.6.2 UAE
    • 10.6.3 Qatar
    • 10.6.4 South Africa
    • 10.6.5 Rest of Middle East & Africa

11 Key Developments

  • 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 11.2 Acquisitions & Mergers
  • 11.3 New Product Launch
  • 11.4 Expansions
  • 11.5 Other Key Strategies

12 Company Profiling

  • 12.1 10x Genomics
  • 12.2 Agilent Technologies
  • 12.3 Becton, Dickinson and Company (BD)
  • 12.4 BGI Genomics
  • 12.5 Bio-Rad Laboratories
  • 12.6 Bio-Techne Corporation
  • 12.7 Bruker
  • 12.8 Danaher Corporation
  • 12.9 Illumina
  • 12.10 Mission Bio
  • 12.11 NanoString Technologies
  • 12.12 Oxford Nanopore Technologies
  • 12.13 Pacific Biosciences (PacBio)
  • 12.14 Revvity
  • 12.15 QIAGEN
  • 12.16 Roche
  • 12.17 Standard BioTools
  • 12.18 Shimadzu Corporation
  • 12.19 Thermo Fisher Scientific
  • 12.20 Human Longevity, Inc.

List of Tables

  • Table 1 Global Multiomics Market Outlook, By Region (2024-2032) ($MN)
  • Table 2 Global Multiomics Market Outlook, By Type (2024-2032) ($MN)
  • Table 3 Global Multiomics Market Outlook, By Genomics (2024-2032) ($MN)
  • Table 4 Global Multiomics Market Outlook, By Transcriptomics (2024-2032) ($MN)
  • Table 5 Global Multiomics Market Outlook, By Proteomics (2024-2032) ($MN)
  • Table 6 Global Multiomics Market Outlook, By Metabolomics (2024-2032) ($MN)
  • Table 7 Global Multiomics Market Outlook, By Epigenomics (2024-2032) ($MN)
  • Table 8 Global Multiomics Market Outlook, By Lipidomics (2024-2032) ($MN)
  • Table 9 Global Multiomics Market Outlook, By Microbiomics (2024-2032) ($MN)
  • Table 10 Global Multiomics Market Outlook, By Product & Service (2024-2032) ($MN)
  • Table 11 Global Multiomics Market Outlook, By Instruments (2024-2032) ($MN)
  • Table 12 Global Multiomics Market Outlook, By Sequencing Instruments (2024-2032) ($MN)
  • Table 13 Global Multiomics Market Outlook, By Mass Spectrometers (2024-2032) ($MN)
  • Table 14 Global Multiomics Market Outlook, By Chromatography Systems (2024-2032) ($MN)
  • Table 15 Global Multiomics Market Outlook, By Microarrays (2024-2032) ($MN)
  • Table 16 Global Multiomics Market Outlook, By Consumables (2024-2032) ($MN)
  • Table 17 Global Multiomics Market Outlook, By Reagents & Kits (2024-2032) ($MN)
  • Table 18 Global Multiomics Market Outlook, By Assay Kits (2024-2032) ($MN)
  • Table 19 Global Multiomics Market Outlook, By Sample Preparation Kits (2024-2032) ($MN)
  • Table 20 Global Multiomics Market Outlook, By Software & Analytics Platforms (2024-2032) ($MN)
  • Table 21 Global Multiomics Market Outlook, By Data Integration & Visualization Tools (2024-2032) ($MN)
  • Table 22 Global Multiomics Market Outlook, By AI/ML Platforms (2024-2032) ($MN)
  • Table 23 Global Multiomics Market Outlook, By Services (2024-2032) ($MN)
  • Table 24 Global Multiomics Market Outlook, By Multiomics Data Analysis (2024-2032) ($MN)
  • Table 25 Global Multiomics Market Outlook, By Custom Services (2024-2032) ($MN)
  • Table 26 Global Multiomics Market Outlook, By Contract Research Services (2024-2032) ($MN)
  • Table 27 Global Multiomics Market Outlook, By Technology (2024-2032) ($MN)
  • Table 28 Global Multiomics Market Outlook, By Single-Cell Multiomics (2024-2032) ($MN)
  • Table 29 Global Multiomics Market Outlook, By Bulk Multiomics (2024-2032) ($MN)
  • Table 30 Global Multiomics Market Outlook, By Spatial Multiomics (2024-2032) ($MN)
  • Table 31 Global Multiomics Market Outlook, By Application (2024-2032) ($MN)
  • Table 32 Global Multiomics Market Outlook, By Drug Discovery & Development (2024-2032) ($MN)
  • Table 33 Global Multiomics Market Outlook, By Precision Medicine (2024-2032) ($MN)
  • Table 34 Global Multiomics Market Outlook, By Biomarker Discovery (2024-2032) ($MN)
  • Table 35 Global Multiomics Market Outlook, By Clinical Diagnostics (2024-2032) ($MN)
  • Table 36 Global Multiomics Market Outlook, By Agrigenomics (2024-2032) ($MN)
  • Table 37 Global Multiomics Market Outlook, By Personalized Nutrition (2024-2032) ($MN)
  • Table 38 Global Multiomics Market Outlook, By Environmental Research (2024-2032) ($MN)
  • Table 39 Global Multiomics Market Outlook, By Microbiome Analysis (2024-2032) ($MN)
  • Table 40 Global Multiomics Market Outlook, By Other Applications (2024-2032) ($MN)
  • Table 41 Global Multiomics Market Outlook, By End User (2024-2032) ($MN)
  • Table 42 Global Multiomics Market Outlook, By Pharmaceutical & Biotechnology Companies (2024-2032) ($MN)
  • Table 43 Global Multiomics Market Outlook, By Academic & Research Institutes (2024-2032) ($MN)
  • Table 44 Global Multiomics Market Outlook, By Hospitals & Clinics (2024-2032) ($MN)
  • Table 45 Global Multiomics Market Outlook, By CROs & CDMOs (2024-2032) ($MN)
  • Table 46 Global Multiomics Market Outlook, By Diagnostic Laboratories (2024-2032) ($MN)
  • Table 47 Global Multiomics Market Outlook, By Agrigenomics Companies (2024-2032) ($MN)
  • Table 48 Global Multiomics Market Outlook, By Other End Users (2024-2032) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.